Duvall, Adam
Mayo Clinic
University of Utah, Salt Lake City, Utah, United States.
Citations 2
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma
Dumke, Henry , Thiruvengadam, Swetha Kambhampati, Argao, Christine, Schroers‐Martin, Joseph G. , Lanka, Sree M , Sawalha, Yazeed , Alharthy, Hanan , Ahmed, Sairah , Okcu, Izel, Nowakowski, Grzegorz S. , Doukas, Peter , Shanmugasundaram, Krithika , Colton, Meryl, Spinner, Michael A. , Rodriguez, Stefania M. , Lakin, Brock G., D’Angelo, Christopher R., Kamdar, Manali, Adewale, Olutobi, Baron, Margaret Kelsey , Bock, Allison M. , Geer, Marcus , Karimi, Yasmin , Dumke, Henry , Schroers-Martin, Joseph G , Lanka, Sree , Sawalha, Yazeed , Alharthy, Hanan , Ahmed, Sairah , Doukas, Peter G , Karmali, Reem , Shanmugasundaram, Krithika , Duvall, Adam , Pizzuti, Vincenzo J , Adewale, Olutobi , Rhodes, Joanna , Tiger, Yun Kyoung Ryu, Baron, Kelsey , Bock, Allison M , Geer, Marcus J , Karimi, Yasmin H , Yang, Xi , Thiruvengadam, Swetha Kambhampati, Karmali, Reem , Colton, Meryl D. , DuVall, Adam , D’Angelo, Christopher R. , Pizzuti, Vincenzo J. , Kamdar, Manali , Rhodes, Joanna , Tiger, Yun Kyoung
Blood Advances | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
10.1182/bloodadvances.2026020965
Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of large B-cell lymphoma (LBCL) with around 90% of patients cured with frontline treatment. For relapsed or refractory (R/R) disease, the optimal treatment is unclear. CD19 chimeric antigen receptor-T cell (CAR-T) has been established as the preferred second line (2L) treatment for primary refractory or early relapsing LBCL based on the overall survival benefits observed in the landmark phase III trials. However, PMBCL patients were underrepresented on these pivotal studies. This study evaluated outcomes of 252 patients treated with 2L therapies for R/R PMBCL at 14 US institutions between 2001 and 2025. Platinum-based salvage with intent to proceed to high dose therapy and autologous stem cell transplant (HDT/ASCT) (platinum cohort) and CD19 CAR-T (CAR-T cohort) were given as 2L therapy in the real-world setting in 157 and 26 patients, respectively. Overall response rate (ORR), complete response (CR) rate and median progression-free survival (PFS) were significantly higher in the CAR-T cohort compared with the platinum cohort (ORR: 91.3% vs 44.2%, p <0.001; CR 65.2% vs 14.7%, p<0.001; median PFS not reached vs 3.5 months, hazard ratio (HR) 0.28, 95% CI 0.15-0.54, p=0.001). No significant difference was observed in overall survival. This study demonstrated superior response rate and PFS of CD19 CAR-T over platinum-based salvage with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.
Disparities in care and outcomes for adolescent and young adult lymphoma patients
DuVall, Adam , Rosenthal, Allison , Duvall, Adam , Kahn, Justine M , Khan, Niloufer
eJHaem | September 28, 2023 | Volume: 4 | Issue: 4 | Pages: 934-939
AbstractThough survival outcomes among adolescents and young adults (AYAs) with lymphoma have improved over the last three decades, socially vulnerable populations including non‐White, low‐income, and publicly insured groups continue to trail behind on survival curves. These disparities, while likely the result of both biological and non‐biological factors, can be largely attributed to inequities in care over the full cancer continuum. Nationally representative studies have demonstrated that from diagnosis through therapy and into long‐term survivorship, socially vulnerable AYAs with lymphoma face barriers to care that impact their short and long‐term survival. Thus, improving outcomes for all AYAs with lymphoma requires dedicated study to understand, and then address the unique challenges faced by non‐White and low‐income lymphoma populations within this age group.